Plus   Neg

ANI Pharma Guides FY20 Below Estimates - Quick Facts

While reporting financial results for the fourth quarter on Thursday, ANI Pharmaceuticals Inc. (ANIP) initiated its adjusted earnings and revenue guidance for the full-year 2020, below analysts' estimates.

For fiscal 2020, the company now projects adjusted earnings in a range of $ $4.46 to $4.86 per share on revenues between $213 million and $223 million.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.47 per share on revenues of $229.15 million for the year. Analysts' estimates typically exclude special items.

The company also said it successfully completed its fourth commercial scale batch of both Corticotropin API and the Cortrophin Gel drug product and remains on track to submit its supplemental NDA filing in March 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT